James Berenson

Nov 1, 2024 | cancernetwork.com | James Berenson

BCMA, which is present in both myeloma cells and healthy cells, could suppress immune cells, making patients more susceptible to potentially fatal severe infections, according to James R. Berenson, MD.

Oct 31, 2024 | cancernetwork.com | James Berenson

CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about advantages BCMA offers in monitoring myeloma progression over conventional biomarkers. Berenson began by highlighting the multiple uses of BCMA testing as a means of prognosis, predictability, and monitoring disease status.

Oct 31, 2024 | cancernetwork.com | James Berenson

Higher BCMA levels are found in patients with myeloma than healthy individuals, and levels are higher in active myeloma than smoldering myeloma, according to James R. Berenson, MD. CancerNetwork® spoke with Berenson, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about how BCMA serum is used to assess patient risk for multiple myeloma.

Sep 30, 2024 | cancernetwork.com | James Berenson

CancerNetwork® spoke with James R. Berenson, MD, about the potential role that JAK inhibitors may play in the treatment of patients with multiple myeloma. The conversation focused on the rationale for researching this drug class as well as ongoing initiatives to assess the utility of agents like ruxolitinib (Jakafi) for this patient population.

Sep 25, 2024 | cancernetwork.com | James Berenson

Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in patients with multiple myeloma, according to James R. Berenson, MD. CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research, and private practitioner in West Hollywood, California, about ongoing trials exploring JAK inhibitors in myeloma.